Table 2 Baseline characteristics of the treatment population (n = 31) at the time of study enrollment
From: A phase IB study of ipilimumab with peginterferon alfa-2b in patients with unresectable melanoma
Baseline Characterisitcs of Treatment Population (n = 31) | |
|---|---|
Median age (range) | 65 (38–83) |
Gender, n (%) | |
Male | 18 (58.1%) |
Female | 13 (41.9%) |
ECOG performance status | |
0 | 11 (35.5%) |
1 | 20 (64.5%) |
Primary site, n (%) | |
Cutaneous | 24 (77.4%) |
Unknown | 5 (16.1%) |
Acral | 2 (6.5%) |
M substage, n (%) | |
M1a | 3 (9.7%) |
M1b | 9 (29.0%) |
M1c | 19 (61.3%) |
LDH level, n (%) | |
Normal | 25 (80.6%) |
Elevated | 6 (19.4%) |
BRAF V600, n (%) | |
wild type | 26 (83.9%) |
V600E | 3 (9.7%) |
V600K | 2 (6.5%) |
Prior systemic therapy, n (%) | |
None | 28 (90.3%) |
BRAF targeted therapy | 1 (3.2%) |
cytotoxic chemotherapy | 1 (3.2%) |
adjuvant vaccine clinical trial | 1 (3.2%) |